Skip to content
Axcess News – Lifestyle
Author:
Propanc Biopharma, Inc.
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
March 24, 2026
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
March 12, 2026
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
March 10, 2026
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
March 6, 2026
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
March 4, 2026
←
Previous Page
1
2